Clinical Trial Update: Safety & Efficacy Study of Subcutaneous Tetrodotoxin for Moderate to Severe Inadequately Controlled Cancer-related Pain [Phase 3]

View source ↗

Summary

Phase 3 study evaluating the safety and efficacy of subcutaneous tetrodotoxin for moderate to severe cancer-related pain has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Tetrodotoxin (tetrodotoxin)

Snippet

Sponsor: Wex Pharmaceuticals Inc. | Conditions: Pain, Cancer | Phase 3 | Status: COMPLETED